• Participación de células troncales tumorales en la progresión de neoplasias.
• Identificación de blancos terapéuticos y desarrollo de nuevos agentes con actividad antineoplásica / antimetastásica.
• Evaluación preclínica de fármacos biológicos y biotecnológicos.

Dr. Marco Velasco Velázquez
Profesor Títular

Dra. Nohemia Salinas Jazmín
Profesor Títular

Dr. Luis Córdova Bahena
Catedrático CONACYT

M. en C. Sandra L. Guerrero Rodríguez
Técnico Académico Titular

-Estudiantes de posgrado

Cecilia Mata Cruz
(Doctorado en C. Bioquímicas)

Milton Abraham Gómez Hernández
(Doctorado en C. Biomédicas)

Ricardo González Salguero
(Maestría en C. Bioquímicas)

1. Hernández-Rojas R, Jiménez-Arellano C, De la Fuente-Granada M, Ordaz-Rosado D, García-Becerra R, Valencia-Mayoral P, Álvarez-Arellano ML, Velasco-Velázquez M, González-Arenas A. The interplay between estrogen receptor beta and PKCs, a crucial collaboration for medulloblastoma cell proliferation and invasion. Cell. Signal. In press, 2022.

2. Cordova-Bahena L, Sánchez-Álvarez AA, Ruiz-Moreno A, Velasco-Velázquez MA*. Repositioning of etravirine as a potential CK1ε inhibitor by virtual screening. Pharmaceuticals 15: 8, 2022. [doi: 10.3390/ph15010008].

3. Hernandez-Peralta P, García-Espejo DA, Gracia-Mora MI, Velasco-Velázquez MA, Cobos-Marín L. Agave mapisaga aqueous extract shows in vitro and in vivo activity on murine prostate cancer cells. Bol. Latinoam. Caribe Plantas Med. Aromát. In press, 2022.

4. Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno, AJ, Monti A, Wang C, Azad T, Bell J, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Dömling A, van Goor H, Groves MR. Synthetic Peptides that antagonise the Angiotensin-Converting Enzyme-2 (ACE-2) interaction with SARS-CoV-2 receptor binding spike protein S. J. Med. Chem. In press, 2022. [doi: 10.1021/acs.jmedchem.1c00477].

5. Salinas-Jazmín N, Rosas-Cruz A, Velasco-Velázquez MA*. Reporter gene systems for the identification and characterization of cancer stem cells. World J. Stem Cells. 13: 1-15, 2021 [doi: 10.4252/wjsc.v13.i7.861].

6. Rosas-Cruz A, Salinas-Jazmín N*, Velasco-Velázquez MA*. Dopamine receptors in cancer: are they valid therapeutic targets? Technol. Cancer Res. Treat. 20: 1-13, 2021 [doi: 10.1177/15330338211027913].

7. Arcos-Montoya D, Wegman-Ostrosky T, Mejía-Pérez S, de la Fuente-Granada M, Camacho-Arroyo I, García-Carrancá A, Velasco-Velázquez MA, Manjarrez-Marmolejo J, Gonzalez-Arenas A. Progesterone receptor phosphorylation together with PKCα expression as a prognostic factor for astrocytomas malignancy. Onco Targets Ther. 14: 3757-3768, 2021 [doi: 10.2147/OTT.S280314].

8. Ruiz-Moreno AJ, Reyes Romero A, Dömling A, Velasco-Velázquez MA*. In silico design and selection of new tetrahydroisoquinoline-based CD44 antagonist candidates. Molecules 26: 1877, 2021 [doi: 10.3390/molecules26071877].

9. Oerlemans R, Ruiz-Moreno AJ, Cong Y, Kumar ND, Velasco-Velázquez MA, Neochoritis C, Smith J, Reggiori F, Groves M, Dömling A. Repurposing the HCV NS3-4A Protease Drug Boceprevir as COVID-19 Therapeutics. RSC Med. Chem. 12: 370, 2021 [doi: 10.1039/d0md00367k].

10. Mejía-Calvo I, López-Juárez LE, Vázquez-Leyva s, López-Morales C, Montoya-Escutia D, Merlos Rivera P, Herbert-Pucheta JE, Zepeda-Vallejo LG, Velasco-Velázquez M, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care. J. Cosmet. Dermatol. 20: 150-158, 2021 [doi:10.1111/jocd.13439].

11. Reyes-Romero A, Ruiz-Moreno AJ, Groves MR, Velasco-Velázquez M, Dömling A. Benchmark of Generic Shapes for Macrocycles. J. Chem. Inf. Mod. 60: 6298-6313, 2020 [doi: 10.1021/acs.jcim.0c01038].

12. Cordova-Bahena L, Velasco-Velázquez MA*. Anti-PD1 and anti-PD-L1 antibodies as immunotherapy against cancer: a structural perspective. Rev. Invest. Clin. 73: 3-11, 2021 [doi:10.24875/RIC.20000341].

13. Li J, Di Lorenzo V, Patil P, Ruiz-Moreno AJ, Kurpiewska K, Kalinowska-Tłuścik J, Velasco-Velázquez MA, Dömling A. Scaffolding-induced property modulation of chemical space. ACS Comb. Sci. 22: 356–360, 2020 [doi:10.1021/acscombsci.0c00072].

14. Camacho-Sandoval R, Jiménez-Uribe A, Tenorio-Calvo A, López-Morales CA, Muñoz-García L, Montes-Luna A, García-Xolalpa HL, Velasco-Velázquez MA, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Taking advantage of a high-throughput flow cytometer for the implementation of ADCC assay for regulatory compliance. Biotechnol. Rep. 26: e00456, 2020 [doi:10.1016/j.btre.2020.e00456].

15. Melgarejo-Rubio G, Pérez Tapia SM, Medina-Rivero E, Velasco-Velázquez MA*. Anticuerpos monoclonales conjugados a fármacos citotóxicos para el tratamiento del cáncer. Gac. Med. Mex. 156: 1-9, 2020 [doi:10.24875/GMM.20000388].

16. Perdomo-Abúndez FC, Vallejo-Castillo L, Vázquez-Leyva S, López-Morales CA, Velasco-Velazquez M, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. J Chromatogr B Analyt Technol Biomed Life Sci. 1139: 121885, 2020 [doi:10.1016/j.jchromb.2019.121885].

17. Velázquez-Quesada I, Ruiz-Moreno AJ, Casique-Aguirre D, Aguirre-Alvarado C, Cortés-Mendoza F, de la Fuente-Granada M, García-Pérez CA, Pérez-Tapia SM, González-Arenas A, Segura-Cabrera A, Velasco-Velázquez MA*. Pranlukast antagonizes CD49f and reduces stemness in triple negative breast cancer cells. Drug Des. Devel. Ther. 14: 1799-1811, 2020 [doi:10.2147/DDDT.S247730].

18. Pérez-Tapia SM, Vallejo-Castillo L, López-Morales CA, Mellado-Sánchez G, Pavón L, Nieto-Patlan L, Velasco-Velázquez MA, Medina-Rivero E, Estrada-Parra S. Transferon® en el 2020. Revista Bio Ciencias 7: e901, 2020 [doi:10.15741/revbio.07.e901].

19. Carballo-Uicab G, Linares-Trejo JE, Mellado-Sanchez G, López-Morales CA, Velasco-Velazquez M, Pavon L, Estrada-Parra S, Pérez-Tapia SM, Medina-Rivero E. Validation of a cell proliferation assay to assess the potency of a Dialyzed Leucocyte Extract intended for batch release. Molecules 24: 3426, 2019 [doi: 10.3390/molecules24193426].

20. Mejía-Calvo I, Muñoz-García L, Jiménez-Uribe A, Camacho-Sandoval R, González-González E, Mellado-Sánchez G, Tenorio-Calvo A, López-Morales CA, Velasco-Velázquez MA, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons. Biotechnol. Rep. 22: article e00331, 2019 [doi: 10.1016/j.btre.2019.e00331].

21. Vásquez-Bochm LX, Velázquez-Paniagua M, Castro-Vázquez S, Guerrero-Rodríguez SL, Mondragón-Peralta A, de la Fuente-Granada M, Pérez-Tapia SM, Gonzalez-Arenas A, Velasco-Velázquez MA*. Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug. Pharmacol. Rep. 71: 535-544, 2019. [doi:10.1016/j.pharep.2019.02.011].

22. Valdés-Rives SA, de la Fuente-Granada M, Velasco-Velázquez MA, González-Flores O, Gonzalez-Arenas A. LPA1 receptor activation induces PKCα nuclear translocation in glioblastoma cells. Int. J. Biochem. Cell Biol. 110: 91-102, 2019 [doi: 10.1016/j.biocel.2019.03.003].

23. López-Morales CA, Vázquez-Leyva S, Vallejo-Castillo L, Carballo-Uicab G, Muñoz-García L, Hebert-Pucheta JE, Zepeda-Vallejo LG, Velasco-Velázquez M, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Determination of peptide profile consistency and safety of collagen hydrolysates as quality attributes. J. Food Sci. 84: 430-439, 2019 [doi: 10.1111/1750-3841.14466].

24. Vázquez-Leyva S, Castillo-Vallejo L, López-Morales CA, Ávila S, Hebert-Pucheta JE, Zepeda-Vallejo LG, Velasco-Velázquez MA, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Identity-profiling of complex peptide-mixture products by structural and mass mobility orthogonal analysis. Anal. Chem. 91: 14392-14400, 2019 [doi: 10.1021/acs.analchem.9b02873].

25. Lara-Chacón B, Guerrero-Rodríguez SL, Ramírez-Hernández KJ; Robledo-Rivera AY, Velasco-Velázquez MA, Sánchez-Olea R, Calera MR. Gpn3 is essential for cell proliferation of breast cancer cells independently of their malignancy degree. Technol. Cancer Res. Treat. 18: 1-11, 2019 [doi: 10.1177/1533033819870823].

26. Velasco-Velázquez MA*, Velázquez-Quesada I, Vásquez-Bochm L, Pérez-Tapia SM. Targeting breast cancer stem cells: a methodological perspective. Curr. Stem Cell Res. Ther. 14(5): 389-397, 2019 [doi: 10.2174/1574888X13666180821155701].

27. Mellado-Sánchez G, Lázaro-Rodríguez JJ, Ávila S, Vallejo-Castillo L, Vázquez-Leyva S, Carballo-Ubicab G, Velasco-Velázquez MA, Medina-Rivero E, Pavón L, Chacón-Salinas R, Pérez-Tapia SM. Development of functional antibodies directed to Human Dialyzable Leukocyte Extract (Transferon®). J. Immunol. Res. 2019: article ID 2754920, 2019 [doi: 10.1155/2019/2754920].

28. Jiménez-Uribe A, Valencia-Martínez H, Carballo-Ubicab G, Vallejo-Castillo L, Medina-Rivero E, Chacón-Salinas R, Pavón L, Velasco-Velázquez MA, Mellado-Sánchez G, Estrada-Parra S, Pérez-Tapia SM. CD80 expression correlates with IL-6 production in THP-1 like macrophages costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). J. Immunol. Res. 2019: article ID 2198508, 2019 [doi: 10.1155/2019/2198508].

28. Jiménez-Uribe A, Valencia-Martínez H, Carballo-Ubicab G, Vallejo-Castillo L, Medina-Rivero E, Chacón-Salinas R, Pavón L, Velasco-Velázquez MA, Mellado-Sánchez G, Estrada-Parra S, Pérez-Tapia SM. CD80 expression correlates with IL-6 production in THP-1 like macrophages costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). J. Immunol. Res. 2019: article ID 2198508, 2019 [doi: 10.1155/2019/2198508].

29. González-González E, Camacho-Sandoval R, Jiménez-Uribe A, Montes-Luna A, Cortes Paniagua I, Sánchez-Morales J, Muñoz-García L, Tenorio-Calvo A, López-Morales CA, Velasco-Velázquez MA, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region. J. Immunol. Methods. 464: 87-94, 2019 [doi: 10.1016/j.jim.2018.11.002].

30. Montaño LM, Flores-Soto E, Reyes-García J, Díaz-Hernández V, Carbajal-García A, Campuzano-González E, Ramírez-Salinas GL, Velasco-Velázquez MA, Sommer B. Testosterone induces hyporesponsiveness to agonists by interfering with IP3 receptors in guinea pig airway smooth muscle. Mol. Cell. Endocrinol. 473: 17-30, 2018 [doi: 10.1016/j.mce.2017.12.010].

31. Matus-Meza AS, Velasco-Velázquez MA, Hernández-Luis F. Design, synthesis and cytotoxic evaluation of quinazoline-2,4,6-triamine and 2,6-diaminoquinazolin-4(3H)-one derivatives. Med. Chem. Res. 27: 1748-1756, 2018 [doi: 10.1007/s00044-018-2188-7].

32. Camacho-Sandoval R, Sosa-Grande EN, González-González E, Tenorio-Calvo AV, López-Morales CA, Velasco-Velázquez MA, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNF-a using flow cytometry detection. J. Pharm. Biomed. Anal. 155: 235–240, 2018 [doi: 10.1016/j.jpba.2018.03.057].

33. Hernández-Esquivel MA, Pérez-Torres A, Romero-Romero L, Reyes-Matute A, Loaiza B, Mellado-Sánchez G, Pavón L, Medina-Rivero E, Pestell RG, Pérez-Tapia SM*, Velasco- Velázquez MA*. The Dialyzable Leukocyte Extract TransferonTM inhibits tumor growth and brain metastasis in a murine model of prostate cancer. Biomed. Pharmacother. 101: 938- 944, 2018 [doi: 10.1016/j.biopha.2018.03.012].

34. Jiao X, Velasco-Velázquez M, Wang M, Li Z, Riu H, Peck AR, Korkola JE, Chen X, Xu S, Duhadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG. CCR5 governs DNA damage repair and breast cancer stem cell expansion. Cancer Res. 78(7): 1657–71, 2018 [doi: 10.1158/0008-5472.CAN-17-0915].

35. Ruiz-Moreno AJ, Torres-Barrera P, Velázquez-Paniagua M, Dömling A, Velasco-Velazquez MA*. Guide for selection of relevant cell lines during the evaluation of new anti-cancer compounds. Anticancer Agents Med. Chem. 18(8): 1072-1081, 2018 [doi: 10.2174/1871520618666180220120544].

35. Pérez-Sánchez G, Becerril-Villanueva E, Arreola R, Martínez-Levy G, Hernández ME, Velasco-Velázquez MA, Álvarez-Herrera S, Cruz-Fuentes C, Palacios L, De la Peña F, Pavón L. Inflammatory profiles in depressed adolescents treated with fluoxetine: an 8-week follow-up, open study. Mediators Inflamm. 2018: article ID 4074051, 2018 [doi: 10.1155/2018/4074051].